The Investigational New Drug (IND) application is a critical step in the drug development process, allowing sponsors to begin clinical trials in humans. This application must adhere to stringent regulations set forth by the FDA, ensuring that the proposed investigational drug is safe for initial use in clinical settings. The IND process encompasses various types, including traditional INDs, expanded access INDs, and emergency use INDs, each serving distinct purposes in drug development and patient access.
In the context of increasing pressure for rapid drug development, particularly highlighted during public health emergencies, understanding the nuances of the IND process has never been more vital. Regulatory professionals must navigate these complexities to ensure compliance while facilitating timely access to potentially life-saving therapies. The implications of a well-prepared IND application extend beyond regulatory approval; they can significantly influence market entry strategies and overall portfolio management for pharmaceutical companies.
Start your 7-day trial and see what the database can do →
